Results 21 to 30 of about 10,606 (259)

Impella CP to Impella 5.5 Uninterrupted Upgrade Using a Double Device Technique

ASAIO Journal, 2022
For the first time, we present a novel technique that enables the exchange of the Impella CP (Abiomed Inc., Danvers, Massachusetts, USA) to the Impella 5.5 (Abiomed Inc.) with no interruption of mechanical support in patients with minimal left ventricular reserve.
Ismael Salas De Armas, Manish K. Patel, Mehmet Akay, Jayeshkumar Patel, Branislav Stojkovic, Biswajit Kar, Igor D Gregoric   +6 more
openaire   +4 more sources

Single center first year experience and outcomes with Impella 5.5 left ventricular assist device

Journal of Cardiothoracic Surgery, 2022
Background The Impella 5.5® was approved by the FDA for use for mechanical circulatory support up to 14 days in late 2019 at limited centers in the United States.
Joanna R. Rock, Cynthia A. Kos, Anthony Lemaire, Hirohisa Ikegami, Mark J. Russo, Danyaal Moin, Kenneth Dulnuan, Deepa Iyer   +7 more
doaj   +1 more source

Benefit With Impella?

Journal of the American College of Cardiology, 2010
We are concerned about the report from the Europella registry ([1][1]), which described the use of the Impella 2.5 device (ABIOMED Inc., Danvers, Massachusetts) in 144 European patients undergoing elective high-risk coronary intervention. If this device or any other has merit in an elective, high-
Kirk N. Garratt, David R. Holmes
openaire   +3 more sources

Enhanced recovery from fulminant myocarditis by treatment with the combined use of the Impella left ventricular assist device with extracorporeal membrane oxygenation: a case series

JA Clinical Reports, 2022
Background We experienced two adult cases of fulminant myocarditis with severe cardiogenic shock where Impella left ventricular assist device [left ventricle (LV)-Impella] was concomitantly used with venoarterial extracorporeal membrane oxygenation (V-A ...
Hideyuki Nandate, Tasuku Nishihara, Yukihiro Nakata, Taisuke Hamada, Yasushi Takasaki, Toshihiro Yorozuya   +5 more
doaj   +1 more source

Giant cell myocarditis masquerading as orbital myositis with a rapid, fulminant course necessitating mechanical support and heart transplantation. [PDF]

, 2017
Giant cell myocarditis (GCM), a rapidly progressive inflammation of the myocardium, is associated with fulminant heart failure, refractory ventricular arrhythmias, and conduction system abnormalities.
Aksoy, Olcay, Ardehali, Reza, Garg, Vinisha, Huynh, Tracy, Shah, Janki, Tan, Weiyi   +5 more
core   +1 more source

IABP versus Impella Support in Cardiogenic Shock: “In Silico” Study

Journal of Cardiovascular Development and Disease, 2023
Cardiogenic shock (CS) is part of a clinical syndrome consisting of acute left ventricular failure causing severe hypotension leading to inadequate organ and tissue perfusion.
Beatrice De Lazzari, Massimo Capoccia, Roberto Badagliacca, Selim Bozkurt, Claudio De Lazzari   +4 more
doaj   +1 more source

Impella 2.5

Journal of Cardiovascular Translational Research, 2009
Impella 2.5 (Abiomed Inc., Danvers, Ma.) is a percutaneous microaxial circulatory support pump that delivers up to 2.5 l/min of systemic flow augmentation by pumping directly from the left ventricle into the ascending aorta. This article describes the device including the insertion method, fundamental principles of action, and clinical results from the
Daniel H. Raess, David M. Weber
openaire   +3 more sources

Complete Revascularisation in Impella-Supported Infarct-Related Cardiogenic Shock Patients Is Associated With Improved Mortality

Frontiers in Cardiovascular Medicine, 2021
Background: Acute myocardial infarction-related cardiogenic shock (AMI-CS) still has high likelihood of in-hospital mortality. The only trial evidence currently available for the intra-aortic balloon pump showed no benefit of its routine use in AMI-CS ...
Andreas Schäfer, Ralf Westenfeld, Jan-Thorben Sieweke, Andreas Zietzer, Julian Wiora, Giulia Masiero, Carolina Sanchez Martinez, Giuseppe Tarantini, Nikos Werner, Nikos Werner   +9 more
doaj   +1 more source

Transaxillary implantation of the Impella CP mechanical circulatory support device as a bridge to heart transplant: first experience in Spain [PDF]

, 2017
Carta ...
Couto-Mallón, David, Crespo-Leiro, María Generosa, Cuenca-Castillo, José J., Estévez-Cid, Francisco, García-Velasco, Carlos, Solla-Buceta, Miguel   +5 more
core   +2 more sources

Impella 5.0 supported oncological surgery as bridge to LVAD

ESC Heart Failure, 2021
We describe the case of a 58‐year‐old man presenting with myocardial infarction complicated by cardiogenic shock, treated with Impella CP which was escalated to an axillary 5.0 due to lack of cardiac recovery.
Andrea Montisci, Giancarlo Micheletto, Serena Sibilio, Francesco Donatelli, Maurizio Tespili, Carlo Banfi, Francesco Casilli, Daniele Cosseta, Antonio Miceli, Silvia Cirri, Federico Pappalardo   +10 more
doaj   +1 more source